瑞舒伐他汀对缺血性脑卒中患者血清TCTGLDL-C及HDL-C水平变化的影响

Effects of rosuvastatin on serum TC,TG,LDL-C and HDL-C levels in patients with ischemic stroke

目的探讨瑞舒伐他汀对缺血性脑卒中患者血清三酰甘油(TG)、总胆固醇(TC)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)水平变化的影响。方法选取平煤神马医疗集团总医院收治的68例缺血性脑卒中患者,依据建档顺序分为2组各34例。对照组采用常规治疗措施,研究组在常规治疗基础上加用瑞舒伐他汀,连续服用6个月。统计对比2组入院时及疗程结束后血清TG、TC、HDL-C、LDL-C水平及神经功能缺损评分(NIHSS)、日常生活活动能力评分(BI)、血清炎症因子[白细胞介素-6(IL-6)、IL-10、IL-17]水平变化情况,并统计对比2组不良反应发生率。结果治疗前2组TG、TC、HDL-C、LDL-C水平比较,差异无统计学意义(P>0.05),治疗后研究组TG、TC、LDL-C水平低于对照组,HDL-C水平高于对照组,差异有统计学意义(P<0.05);治疗前2组NIHSS评分及BI评分比较,差异无统计学意义(P>0.05),治疗后研究组NIHSS评分低于对照组,BI评分高于对照组,差异有统计学意义(P<0.05);治疗前2组IL-6、IL-10、IL-17水平比较,差异无统计学意义(P>0.05),治疗后研究组IL-6、IL-17水平低于对照组,IL-10水平高于对照组,差异有统计学意义(P<0.05);研究组不良反应发生率(17.64%)与对照组(14.70%)比较,差异无统计学意义(P>0.05)。结论采用瑞舒伐他汀治疗缺血性脑卒中效果显著,可有效改善患者血脂及血清炎症因子水平,提高神经功能及日常生活能力,且安全性较高。

Objective To investigate the effects of rosuvastatin on serum triglyceride （TG）,total cholesterol （TC）,high density lipoprotein cholesterol （HDL-C） and low density lipoprotein cholesterol （LDL-C） levels in patients with ischemic stroke. Methods 68 patients with ischemic stroke from March,2014 to February,2016 in our hospital assigned to two groups according to the order of filing, each with 34 cases. The control group was treated with conventional therapy. The study group was treated with rosuvastatin on the basis of conventional therapy for 6 months. The levels of serum TG, TC, HDL-C, LDL-C and neurological deficits （NIHSS）,daily living activity score （BI）, serum inflammatory factors[interleukin-6 （IL-6）, IL-10, IL-17]levels change were statistically compared between the two groups at admission and after the course of treatment. We also compared the incidence of adverse reactions between the two groups. Results There was no significant difference in the levels of TG, TC, HDL-C and LDL-C between the two groups before treatment （P〉0.05）. After treatment,the levels of TG,TC and LDL-C in the study group were lower than that in the control group, and the level of HDL-C was higher than that of the control group. The difference was statistically significant （P〈0. 05）. There was no significant difference in NIHSS score and BI score between the two groups before treatment （P〉0.05）. After treatment, the scores of NIHSS in the study group were lower than those in the control group, and the BI score was higher than that of the control group （P〈0.05）. The difference was statistically significant （P〈0. 05）. There was no significant difference in IL-6, IL-10 and IL-17 levels between the two groups before treatment （P〉0. 05）. After treatment, the level of IL-6 and IL-17 in the study group was lower than that in the control group,and the level of IL-10 was higher than that of the control group. The difference was statistically significant （P 〈 0.05）. The incidence of adverse reactions in the study group 17.64% （6/34） was compared with 14.70% in the control group （5/34）. The difference was not statistically significant （P〉0. 05）. Concision The use of rosuvastatin in the treatment of ischemic stroke is significant,which can improve the blood lipid and serum inflammatory factors, improve the neurological function and daily living ability with high safety.